Literature DB >> 12679852

Multi parameter in vitro testing of ratjadone using flow cytometry.

A Burzlaff1, M Kalesse, C Kasper, T Scheper.   

Abstract

Ratjadone, isolated from the myxobacterium Sorangium cellulosum, belongs to the family of so-called orphan ligands, which includes leptomycin, callystatin and other compounds. In previous screening tests, ratjadone revealed a growth inhibitory effect against bacteria, yeast and human cancer cells. Following these first results, ratjadone was tested on several human tumour cell lines (Jurkat, HepG2, U87-MG) and, as a control, on a non-tumour cell line (RLC18) for its mode of action. The cell analysis was carried out by flow cytometry. This comprised cell density measurements, live-dead analysis, cell-cycle analysis and detection of apoptosis. First experiments confirmed the growth inhibitory effect on any chosen tumour cell line. Following these results a dose effect relationship was monitored, confirming the high effectiveness of ratjadone against cell growth at nanomolar concentration. Cell cycle analysis has shown that ratjadone intervenes in the cell cycle by arresting the cells in G1-phase. Biological testing of additional ratjadone derivatives with changed configuration and stereochemistry, identified the pharmacophoric site of the molecule.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12679852     DOI: 10.1007/s00253-003-1300-0

Source DB:  PubMed          Journal:  Appl Microbiol Biotechnol        ISSN: 0175-7598            Impact factor:   4.813


  9 in total

Review 1.  Expression, function, and targeting of the nuclear exporter chromosome region maintenance 1 (CRM1) protein.

Authors:  Jo Ishizawa; Kensuke Kojima; Numsen Hail; Yoko Tabe; Michael Andreeff
Journal:  Pharmacol Ther       Date:  2015-06-03       Impact factor: 12.310

Review 2.  Nuclear export of proteins and drug resistance in cancer.

Authors:  Joel G Turner; Jana Dawson; Daniel M Sullivan
Journal:  Biochem Pharmacol       Date:  2011-12-20       Impact factor: 5.858

3.  Human multiple myeloma cells are sensitized to topoisomerase II inhibitors by CRM1 inhibition.

Authors:  Joel G Turner; Douglas C Marchion; Jana L Dawson; Michael F Emmons; Lori A Hazlehurst; Peter Washausen; Daniel M Sullivan
Journal:  Cancer Res       Date:  2009-08-18       Impact factor: 12.701

4.  CRM1 Inhibition Sensitizes Drug Resistant Human Myeloma Cells to Topoisomerase II and Proteasome Inhibitors both In Vitro and Ex Vivo.

Authors:  Joel G Turner; Jana Dawson; Michael F Emmons; Christopher L Cubitt; Michael Kauffman; Sharon Shacham; Lori A Hazlehurst; Daniel M Sullivan
Journal:  J Cancer       Date:  2013-09-10       Impact factor: 4.207

Review 5.  Nucleo-cytoplasmic transport as a therapeutic target of cancer.

Authors:  Giovanni Luca Gravina; William Senapedis; Dilara McCauley; Erkan Baloglu; Sharon Shacham; Claudio Festuccia
Journal:  J Hematol Oncol       Date:  2014-12-05       Impact factor: 17.388

Review 6.  CRM1 Inhibitors for Antiviral Therapy.

Authors:  Cynthia Mathew; Reena Ghildyal
Journal:  Front Microbiol       Date:  2017-06-28       Impact factor: 5.640

Review 7.  Controlling the Gatekeeper: Therapeutic Targeting of Nuclear Transport.

Authors:  Friederike K Kosyna; Reinhard Depping
Journal:  Cells       Date:  2018-11-21       Impact factor: 6.600

Review 8.  New Insights into the Link between Melanoma and Thyroid Cancer: Role of Nucleocytoplasmic Trafficking.

Authors:  Mourad Zerfaoui; Titilope Modupe Dokunmu; Eman Ali Toraih; Bashir M Rezk; Zakaria Y Abd Elmageed; Emad Kandil
Journal:  Cells       Date:  2021-02-10       Impact factor: 6.600

Review 9.  Targeting Nuclear Export Proteins in Multiple Myeloma Therapy.

Authors:  Nicholas Theodoropoulos; Guido Lancman; Ajai Chari
Journal:  Target Oncol       Date:  2020-12       Impact factor: 4.493

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.